ABSTRACT Eighteen patients with sustained ventricular tachycardia underwent electrophysiologic studies to establish the therapeutic efficacy of sotalol. In each patient ventricular tachycardia could be reproducibly initiated by programmed stimulation during control studies. Sotalol prevented induction of sustained ventricular tachycardia in 12 of the 18 patients (67%). Prolongation of the QTC interval and of ventricular refractoriness was regularly observed after sotalol but did not reliably predict prophylactic efficacy. Severe adverse effects, including congestive heart failure and sinus node dysfunction, were noted early during sotalol therapy in three patients. Nine patients were placed on long-term oral treatment with sotalol and four patients on another effective agent. In these 13 patients, complete (12 patients) or partial (one patient) long-term prophylaxis against ventricular tachycardia was documented over a mean follow-up period of 16 months (range 8 to 24). The study suggests that sotalol can provide effective prophylaxis against sustained ventricular tachycardia; this prophylactic efficacy is not typical for pure f3-adrenergic antagonism but may at least partly result from experimentally observed prolongation of the ventricular action potential duration. Circulation 69, No. 3, 577-584, 1984. SOTALOL is a noncardioselective, /B-adrenergicblocking drug without intrinsic sympathomimetic or membrane-stabilizing activity. Among other /3-blocking drugs, sotalol is unique by its additional class III activity resulting in short-term prolongation of the repolarization in a variety of types of cardiac fiber." 2 This unusual combination of antiarrhythmic properties should be beneficial in the treatment of various arrhythmias and, more importantly, in the prevention of sudden cardiac death caused by ventricular fibrillation. The latter hypothesis was not confirmed in a recent trial, in which a single dose of 320 mg of sotalol was given once daily to patients who had suffered myocardial infarction.3 However, this regimen might not have resulted in consistent maintenance of prophylactic plasma concentrations and, moreover, sotalol could have reduced mortality in a special subgroup of postinfarction patients with complex ventricular arrhythmias. Earlier studies have demonstrated a moderate antiarrhythmic efficacy of sotalol on a variety of supraventricular and ventricular arrhythmias.`However, these studies included groups with heterogeneous arrhythmias and only a few ventricular tachycardias. Furthermore, a reduction in frequency and grade of spontaneously occurring ventricular arrhythmias was used as the end point by which antiarrhythmic efficacy was assessed. None of these studies described the effects of sotalol on electrophysiologic parameters, including ventricular refractoriness and, moreover, often only the short-term suppression of arrhythmias was reported without long-term follow-up.
SOTALOL is a noncardioselective, /B-adrenergicblocking drug without intrinsic sympathomimetic or membrane-stabilizing activity. Among other /3-blocking drugs, sotalol is unique by its additional class III activity resulting in short-term prolongation of the repolarization in a variety of types of cardiac fiber." 2 This unusual combination of antiarrhythmic properties should be beneficial in the treatment of various arrhythmias and, more importantly, in the prevention of sudden cardiac death caused by ventricular fibrillation. The latter hypothesis was not confirmed in a recent trial, in which a single dose of 320 mg of sotalol was given once daily to patients who had suffered myocardial infarction.3 However, this regimen might not have resulted in consistent maintenance of prophylactic plasma concentrations and, moreover, sotalol could have reduced mortality in a special subgroup of postinfarction patients with complex ventricular arrhythmias. studies included groups with heterogeneous arrhythmias and only a few ventricular tachycardias. Furthermore, a reduction in frequency and grade of spontaneously occurring ventricular arrhythmias was used as the end point by which antiarrhythmic efficacy was assessed. None of these studies described the effects of sotalol on electrophysiologic parameters, including ventricular refractoriness and, moreover, often only the short-term suppression of arrhythmias was reported without long-term follow-up.
The purpose of this study was (1) to determine the short-term preventive effect of a high dose of sotalol (1.5 mg/kg) by means of electrophysiologic testing in selected patients with sustained ventricular tachycardia and (2) to evaluate the long-term efficacy of sotalol.
Methods
Patients. Eighteen patients with sustained ventricular tachycardia or ventricular fibrillation underwent electrophysiologic studies to test the efficacy of sotalol. All patients had one or more documented spontaneous episode of symptomatic sustained ventricular tachycardia (15 Initial electrophysiologic study. All patients gave written informed consent and were studied in a postabsorptive state. They were given either no premedication or were sedated with oral diazepam. Except digoxin, which was being used by 10 patients, all antiarrhythmic medication was discontinued at least four half-lives of each drug before the initial study. Three quadripolar electrode catheters with a 1 cm interelectrode distance were inserted percutaneously through femoral and antecubital veins and were positioned in the heart under fluoroscopic guidance. The distal pair of the electrodes was used for stimulation and the proximal pair for recording local electrograms. Intracardiac recordings from the lateral right atrium. the bundle of His, and the ventricular apex were filtered at 40 to 500 Hz and displayed simultaneously with surface electrocardiographic leads I, aVF, and V, on a multichannel oscilloscope (Electronics for Medicine, ; the signals were recorded on paper at speeds of 50 and 100 mm/sec.
Cardiac stimulation was performed with a programmable constant-current stimulator (Medtronic) that delivered rectangular pulses of 2 msec duration. All ventricular stimulation was carried out at the right ventricular apex at twice diastolic threshold. The following stimulation protocol was used8: (1) rapid atrial pacing at cycle lengths from 600 to 300 msec; (2) Among those 13 patients the following patterns of inducible ventricular arrhythmias were found: complete suppression of all arrhythmias in five patients, repetitive ventricular response (three to five complexes) in six patients, and short episodes of nonsustained ventricular tachycardia (six to 15 complexes) in two patients.
Repeat intracardiac stimulation after oral administration of sotalol was performed in 11 of these 13 patients and prophylactic effects were reproduced in 10 of them. Despite adequate sotalol plasma concentration, suppression of sustained ventricular tachycardia could not be reproduced in one patient (No. 18) who was therefore considered a sotalol nonresponder. In two of the sotalol responders (Nos. 3 and 4) no repeat sotalol study was performed because another effective drug was chosen for oral therapy; sotalol was suggested to be effective in both cases on the basis of intravenous studies only. Thus a total of 12 (66%) of the 18 patients constitute the group of sotalol responders (group A).
In six (33%) of the 18 patients, sotalol was not able to prevent sustained ventricular tachycardia (group B, sotalol nonresponders). 1  650  680  90  90  355  350  440  425  250  260  2  770  960  110  110  360  500  410  510  240  280  3  620  800  90  90  300  400  380  445  230  280  4  800  1180  100  100  360  480  405  440  240  280  5  590  900  80  80  300  400  390  420  6  765  915  95  95  360  455  410  475  250  285  7  700  880  100  100  310  400  370  425  260  310  8  980  1100  110  110  380  440  385  420  250  270  9  735  880  125  125  355  440  415  470  10  700  880  120  120  360  420  430  450  240  280  11  720  900  110  110  290  420  400  440  220  290  12  980  1080  150  170  400  480  405  460  290  310  13  995  1075  120  120  410  475  410  460  14  800  1000  80  90  410  480  460  480  220  265  15  720  740  110  110  340  350  400  410  230  280  16  680  880  100  100  320  390  390  415  17  620  860  120  120  280  400  355  430  230  280  18  740  1030  100  100  360  460  420  455  270  335  Mean  754  930  106  108  347  430  404  446  243 Adverse reactions. After intravenous administration of sotalol two of 18 patients developed mild congestive heart failure; no adverse effects were observed in the other patients. Oral administration of sotalol was initiated in 11 of the 12 sotalol responders. Within the first several days of oral therapy, one other patient developed symptomatic sinus bradycardia (30 to 45 beats/ min) and transient episodes of sinus arrest requiring discontinuation of the drug. One patient (No. 5) died 3 weeks after the study began while on sotalol therapy. This death occurred inside the hospital and was due to myocardial reinfarction followed by cardiogenic shock. In the nine patients maintained on long-term sotalol therapy, no adverse effects appeared late after hospital discharge. In particular, no neurologic or gastrointestinal side effects were reported by any patient.
Comparison to the prophylactic efficacy of quinidine. The short-term efficacy of intravenous quinidine (10 mg/kg over 30 min) was studied in 15 of the 18 patients. In the presence of therapeutic plasma concentrations (3.4 + 0.9 gg/ml; mean ± SD), quinidine prevented sustained ventricular tachycardia in two of nine sotalol responders but in none of the six sotalol nonresponders, resulting in successful prophylaxis in a total of two of 15 patients (13%). Since the numbers of other drugs tested are too small and there was no systematic sequence of administration, comparison between sotalol and additional agents used in this study is not meaningful.
Clinical follow-up. After hospital discharge, 17 patients have been followed for an average of 16 months (range 8 to 24; table 4). In the 13 patients in whom a single orally administered drug prevented the initiation of sustained ventricular tachycardia, that drug was used. In nine patients sotalol was selected for longterm oral administration. Eight of nine patients were completely protected against symptomatic or identifiable ventricular tachycardia throughout the follow-up. One patient had recurrences of ventricular tachycardia. In this patient (No. 8) sotalol had been discontinued 2 days before recurrence of ventricular tachycardia by the referring physician without clinical necessity. After sotalol therapy had been readjusted, the drug continued to be effective. Four patients were placed on one of the other antiarrhythmic drugs found to be effective by electrophysiologic testing. So far, no drug has been discontinued and no symptomatic or identifiable ventricular tachycardia has occurred. The remaining four patients in whom no prophylactic drug was identified were treated with amiodarone or with a combination of amiodarone plus sotalol. This combination was chosen to avoid potentially toxic side effects of higher doses of amiodarone and to test the predictive value of nonpreventive electrophysiologic results on long-term prophylaxis with two drugs having class III activities. Induction of sustained ventricular tachycardia was not prevented in three of the four patients after 2 to 3 weeks of oral administration of amiodarone or in two of these patients after subsequent combination with sotalol (Nos. 15 and 18); one patient was given amiodarone without electrophysiologic studies (No. 13). During the follow-up, only one of the four patients had a good therapeutic response (No. 18). Two other patients continued to have recurrent ventricular tachycardia (Nos. 13 and 14) and one patient died suddenly after rapid deterioration of chronic congestive heart failure within hours (No. 15). This death occurred at the patient's home 7 months after the study began and no electrocardiographic recordings were documented.
During long-term therapy, continuous ambulatory monitoring documented brief, self-terminating, asymptomatic episodes of ventricular tachycardia (three to five complexes) in two patients placed on drugs considered effective (Nos. 4 Adverse effects. Symptomatic sinus node dysfunction and congestive heart failure were the two major adverse effects of sotalol; such effects developed in two of 18 (11%) patients after short-term intravenous administration and in one of 11 (9%) patients within the initial several days of oral administration. The cardiac death observed during hospitalization in one patient was not related to arrhythmias but was caused by myocardial reinfarction followed by cardiogenic shock. In a randomized study of about 1500 patients who had suffered myocardial infarction, the appearance of adverse reactions in the sotalol group exceeded that obtained in the placebo group by only 5%.3 The higher incidence of side effects in the present study may be explained by the relatively small number of highly selected patients, most of whom had extensive myocardial infarction, and by the large doses of sotalol used. No neurologic or gastrointestinal side effects appeared that frequently manifest with class I antiarrhythmic drugs.
Amiodarone is the only other class III antiarrhythmic drug in clinical use; this drug has been documented to exert potent suppressive effects against virtually all kinds of arrhythmias but also to cause a variety of major adverse effects.27 In contrast, the adverse effects of therapeutic doses of sotalol appear to be related predominantly to its fl-blocking properties,' which might be greatly reduced with the d-isomer of this racemic drug. Preliminary results of this laboratory support this hypothesis.
